Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938718 | 0.80 | EPHX1 (0.37) | MIFEPHX1 | |
| SCHEMBL3748652 | 0.80 | TRPA1 (0.40) | MIFSMN1; SMN2EPHX1 | |
| SCHEMBL406396 | 0.80 | MIF (0.39) | MIFSMN1; SMN2L3MBTL1EPHX1 | |
| Hydrochloric Acid SCHEMBL3569025 | 0.79 | EPHX1 (0.36) | MIFEPHX1 | |
| SCHEMBL1464588 | 0.79 | CTSC (0.36) | ESR1ESR2MAOBSMN1; SMN2L3MBTL1 | |
| SCHEMBL3208887 | 0.78 | MIF (0.37) | MIFSMN1; SMN2L3MBTL1EPHX1 | |
| SCHEMBL1430902 | 0.77 | MIF (0.56) | MIFSMN1; SMN2 | |
| SCHEMBL3558393 | 0.77 | MIF (0.36) | MIFSMN1; SMN2EPHX1 | |
| SCHEMBL300073 | 0.76 | EPHX1 (0.35) | MIFEPHX1 | |
| SCHEMBL506238 | 0.74 | LMNA (0.37) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011008597-A1 | DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES USEFUL AS PDE10 INHIBITORS | SCHERING CORPORATION (US) | 2011-01-20 | — | — | WO | disclosed |